170 related articles for article (PubMed ID: 17877615)
1. Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy.
Banu N; Buda A; Chell S; Elder D; Moorghen M; Paraskeva C; Qualtrough D; Pignatelli M
Cell Prolif; 2007 Oct; 40(5):768-79. PubMed ID: 17877615
[TBL] [Abstract][Full Text] [Related]
2. The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway.
Zhang H; Ye Y; Bai Z; Wang S
Dig Dis Sci; 2008 Aug; 53(8):2195-203. PubMed ID: 18320325
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms.
Deasy BM; O'Sullivan-Coyne G; O'Donovan TR; McKenna SL; O'Sullivan GC
Cancer Lett; 2007 Oct; 256(2):246-58. PubMed ID: 17707579
[TBL] [Abstract][Full Text] [Related]
5. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
Crew TE; Elder DJ; Paraskeva C
Carcinogenesis; 2000 Jan; 21(1):69-77. PubMed ID: 10607736
[TBL] [Abstract][Full Text] [Related]
6. Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells.
Kim SJ; Seo JH; Lee YJ; Yoon JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Oncology; 2005; 68(2-3):204-11. PubMed ID: 16015035
[TBL] [Abstract][Full Text] [Related]
7. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
[TBL] [Abstract][Full Text] [Related]
8. [Effects of selective cyclooxygenase-2 inhibitor NS-398 on 5-fluorouracil chemotherapy and progression of colon cells: an experimental study].
Zhang YC; Wang S; Zhang H; Ye YJ; Liang B; Cui ZR
Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(7):583-6. PubMed ID: 15144595
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
Han C; Michalopoulos GK; Wu T
J Cell Physiol; 2006 Apr; 207(1):261-70. PubMed ID: 16331686
[TBL] [Abstract][Full Text] [Related]
10. Transactivation of EGFR/PI3K/Akt involved in ATP-induced inflammatory protein expression and cell motility.
Lin CC; Lin WN; Cheng SE; Tung WH; Wang HH; Yang CM
J Cell Physiol; 2012 Apr; 227(4):1628-38. PubMed ID: 21678415
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer.
Yao M; Lam EC; Kelly CR; Zhou W; Wolfe MM
Br J Cancer; 2004 Feb; 90(3):712-9. PubMed ID: 14760389
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic and therapeutic benefits of COX-2 inhibitor on motility dysfunction in bowel obstruction: roles of PGE₂ and EP receptors.
Lin YM; Sarna SK; Shi XZ
Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(2):G267-75. PubMed ID: 22038825
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis.
Rozic JG; Chakraborty C; Lala PK
Int J Cancer; 2001 Aug; 93(4):497-506. PubMed ID: 11477553
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid-induced transactivation of epidermal growth factor receptor regulates cyclo-oxygenase-2 expression and prostaglandin E(2) release via C/EBPbeta in human bronchial epithelial cells.
He D; Natarajan V; Stern R; Gorshkova IA; Solway J; Spannhake EW; Zhao Y
Biochem J; 2008 May; 412(1):153-62. PubMed ID: 18294142
[TBL] [Abstract][Full Text] [Related]
15. Effect of a cyclooxygenase-2 inhibitor on interleukin-1beta-stimulated activation of the transcription factor nuclear factor-kappa B in human gingival fibroblasts.
Tipton DA; Gay DC; DeCoster VA
J Periodontol; 2007 Mar; 78(3):542-9. PubMed ID: 17335379
[TBL] [Abstract][Full Text] [Related]
16. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference.
Denkert C; Fürstenberg A; Daniel PT; Koch I; Köbel M; Weichert W; Siegert A; Hauptmann S
Oncogene; 2003 Nov; 22(54):8653-61. PubMed ID: 14647459
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398.
Elder DJ; Halton DE; Crew TE; Paraskeva C
Int J Cancer; 2000 May; 86(4):553-60. PubMed ID: 10797271
[TBL] [Abstract][Full Text] [Related]
18. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor.
Hu KQ; Yu CH; Mineyama Y; McCracken JD; Hillebrand DJ; Hasan M
Int J Oncol; 2003 Apr; 22(4):757-63. PubMed ID: 12632065
[TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.
Half E; Sun Y; Sinicrope FA
Cancer Lett; 2007 Jun; 251(2):237-46. PubMed ID: 17189670
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells.
Coffey RJ; Hawkey CJ; Damstrup L; Graves-Deal R; Daniel VC; Dempsey PJ; Chinery R; Kirkland SC; DuBois RN; Jetton TL; Morrow JD
Proc Natl Acad Sci U S A; 1997 Jan; 94(2):657-62. PubMed ID: 9012840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
